Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies

Blood

Volumn 126, Issue 21, 2015, Pages 2392-2403

  Matthews, Geoffrey M ^a,b   Mehdipour, Parinaz ^c   Cluse, Leonie A ^a,b   Falkenberg, Katrina J ^a,d,e   Wang, Eric ^f   Roth, Mareike ^d   Santoro, Fabio ^c   Vidacs, Eva ^a,b   Stanley, Kym ^a,b   House, Colin M ^b   Rusche, James R ^g   Vakoc, Christopher R ^f   Zuber, Johannes ^d   Minucci, Saverio ^c,h   Johnstone, Ricky W ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^g REPLIGEN CORPORATION   (United States)

^h UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 3 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 2; PROTEIN P21; UNCLASSIFIED DRUG; VORINOSTAT; BCL2 PROTEIN, MOUSE; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEMATOLOGIC MALIGNANCY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHOMA; LYMPHOMA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TUMOR VOLUME; 3T3 CELL LINE; ANIMAL; ENZYMOLOGY; GENETICS; LEUKEMIA, PROMYELOCYTIC, ACUTE; METABOLISM; PATHOLOGY;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; LEUKEMIA, PROMYELOCYTIC, ACUTE; LYMPHOMA; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84949024001     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-632984     Document Type: Article

References (65)

1. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673-691.
2. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014;124(1):30-39.
3. BantscheffM, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011;29(3):255-265.
4. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
5. Stengel KR, Hiebert SW, Class I. Class I HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy. Antioxid Redox Signal. 2015;23(1):51-65.
6. Xu W, Li Y, Liu C, Zhao S. Protein lysine acetylation guards metabolic homeostasis to fight against cancer. Oncogene. 2014;33(18):2279-2285.
7. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107-116.
8. Odenike O, Halpern A, Godley LA, et al. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Invest New Drugs. 2015;33(2):371-379.
9. Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013;121(8):1296-1303.
10. Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331-2337.
11. San-Miguel JF, Richardson PG, Günther A, et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013;31(29):3696-3703.
12. Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther. 2008;8(3):413-432.
13. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769-784.
14. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8-21.
15. Buchwald M, Krämer OH, Heinzel T. HDACi-targets beyond chromatin. Cancer Lett. 2009;280(2):160-167.
16. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23.
17. Legartová S, Stixov á L, Strnad H, et al. Basic nuclear processes affected by histone acetyltransferases and histone deacetylase inhibitors. Epigenomics. 2013;5(4):379-396.
18. Yang Y, Rao R, Shen J, et al. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res. 2008; 68(12):4833-4842.
19. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4(1):13-18.
20. Ononye SN, van Heyst M, Falcone EM, Anderson AC, Wright DL. Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharm Pat Anal. 2012;1(2):207-221.
21. Minami J, Suzuki R, Mazitschek R, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 2014;28(3):680-689.
22. Wells CE, Bhaskara S, Stengel KR, et al. Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma. PLoS One. 2013;8(7): e68915.
23. Balasubramanian S, Verner E, Buggy JJ. Isoformspecific histone deacetylase inhibitors: the next step? Cancer Lett. 2009;280(2):211-221.
24. Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Em-myc model of B-cell lymphoma. Oncogene. 2014;33(47):5415-5423.
25. Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548-13558.
26. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
27. Minucci S, Monestiroli S, Giavara S, et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood. 2002;100(8):2989-2995.
28. Santoro F, Botrugno OA, Dal Zuffo R, et al. A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood. 2013; 121(17):3459-3468.
29. Newbold A, Matthews GM, Bots M, et al. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Mol Cancer Ther. 2013;12(12):2709-2721.
30. Vert J-P, Foveau N, Lajaunie C, Vandenbrouck Y. An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics. 2006; 7(1):520.
31. Matthews GM, Lefebure M, Doyle MA, et al. Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk∗MYC multiple myeloma. Cell Death Dis. 2013;4: e798.
32. Turgeon ML. Clinical Hematology: Theory and Procedures. Hagerstown, MD: Lippincott Williams & Wilkins; 2005:67.
33. Zuber J, Rappaport AR, Luo W, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated selfrenewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628-1640.
34. published correction appears in Genes Dev. 2011;25(18):1997
35. Zuber J, McJunkin K, Fellmann C, et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol. 2011;29(1):79-83.
36. Malvaez M, McQuown SC, Rogge GA, et al. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci USA. 2013;110(7):2647-2652.
37. Summers AR, Fischer MA, Stengel KR, et al. HDAC3 is essential for DNA replication in hematopoietic progenitor cells. J Clin Invest. 2013;123(7):3112-3123.
38. Dow LE, Premsrirut PK, Zuber J, et al. A pipeline for the generation of shRNA transgenic mice. Nat Protoc. 2012;7(2):374-393.
39. Dow LE, Nasr Z, Saborowski M, et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS One. 2014;9(4): e95236.
40. Lindemann RK, Newbold A, Whitecross KF, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA. 2007;104(19):8071-8076.
41. Huang W, Tan D, Wang X, et al. Histone deacetylase 3 represses p15(INK4b) and p21 (WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun. 2006;339(1):165-171.
42. Jiao F, Hu H, Yuan C, et al. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. Int J Oncol. 2014;45(4):1523-1530.
43. Feng L, Pan M, Sun J, et al. Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells. J Mol Med (Berl). 2013;91(1):49-58.
44. Singh N, Gupta M, Trivedi CM, Singh MK, Li L, Epstein JA. Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression. Dev Biol. 2013;377(2):333-344.
45. Fajas L, Egler V, Reiter R, et al. The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell. 2002;3(6):903-910.
46. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene. 2003;22(27):4186-4193.
47. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 2005; 37(11):1289-1295.
48. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971-975.
49. Teng T, Mercer CA, Hexley P, Thomas G, Fumagalli S. Loss of tumor suppressor RPL5/ RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol Cell Biol. 2013;33(23):4660-4671.
50. Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2008;47(2):137-147.
51. Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One. 2013;8(11): e79781.
52. Gravina GL, Marampon F, Giusti I, et al. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol. 2012;40(3):711-720.
53. Hsieh YJ, Hwu L, Chen YC, et al. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. J Nucl Med. 2014;55(4):678-685.
54. Grimwade D, Mistry AR, Solomon E, Guidez F. Acute promyelocytic leukemia: a paradigm for differentiation therapy. Cancer Treat Res. 2010; 145:219-235.
55. Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001;20(24):3110-3115.
56. Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Mol Cancer Ther. 2014;13(12):2886-2897.
57. Hideshima T, Bradner JE, Wong J, et al. Smallmolecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005; 102(24):8567-8572.
58. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119(11):2579-2589.
59. Ding N, Ping L, Feng L, Zheng X, Song Y, Zhu J. Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells. Cancer Cell Int. 2014;14(1):139.
60. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci USA. 2003;100(8):4389-4394.
61. Zhang L, Liu N, Xie S, et al. HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process. Cancer Biol Ther. 2014; 15(11):1561-1570.
62. Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007;27(13):4784-4795.
63. Wilting RH, Yanover E, Heideman MR, et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J. 2010;29(15):2586-2597.
64. Ellis L, Bots M, Lindemann RK, et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood. 2009;114(2):380-393.
65. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 2003;63(15):4460-4471.